The short version of drug affinity complex fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-11. Anything still debated is marked as such rather than presented as settled.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Although the preponderance of evidence is on the side of a multidimensional measure, the issue has not been fully resolved owing in part to limitations in the methodological knowledge available on distinguishing between substantive and method variance.
Californium-252 (Cf-252, 252Cf) undergoes spontaneous fission with a branching ratio of 3.09% and is used in small neutron sources. Fission neutrons have an energy range of 0 to 13 MeV with a mean value of 2.3 MeV and a most probable value of 1 MeV. This isotope produces high neutron emissions and has a number of uses in industries such as nuclear energy, medicine, and petrochemical exploration.
=== Literature === In Western literature, vegetarianism, and topics that relate to it, have informed a "gamut of literary genres", whether literary fiction or those fictions focusing on utopias, dystopias, or apocalypses, with authors shaped by questions about human identity and "our relation to the environment", implicating vegetarianism and veganism. Others have pointed to the lack of "memorable characters" who are vegetarian. There are also vegetarian themes in horror fiction, science fiction and poetry. In 1818, Mary Shelley published the novel Frankenstein. Writer and animal rights advocate Carol J. Adams argued in her seminal book, The Sexual Politics of Meat that the unnamed creature in the novel was a vegetarian. She argued that the book was "indebted to the vegetarian climate" of its day and that vegetarianism is a major theme in the novel as a whole. She notes that the creature gives an "emotional speech" talking about its dietary principles, which makes it a "more sympathetic being" than others. She also said that it connected with Vegetarianism in the Romantic Era who believed that the Garden of Eden was meatless, rewrote the myth of Prometheus, the ideas of Jean-Jacques Rousseau, and feminist symbolism. Adams concludes that it is more likely that the "vegetarian revelations" in the novel are "silenced" due to the lack of a "framework into which we can assimilate them." Apart from Adams, scholar Suzanne Samples pointed to "gendered spaces of eating and consumption" within Victorian England which influenced literary characters of the time.
Sources: en.wikipedia.org
== Test usage in the life insurance industry == The test has been widely used in the life insurance industry to screen applicants as part of the routine requirements when applying for a life insurance policy. It is also inexpensive and can be measured from blood samples routinely drawn as part of the application process. The test can be used to evaluate for a number of health conditions.
=== Enamels === During the Meiji era, Japanese cloisonné enamel reached a technical peak, producing items more advanced than any that had existed before. The period from 1890 to 1910 was known as the "Golden age" of Japanese enamels. Artists experimented with pastes and with the firing process to produce ever larger blocks of enamel, with less need for cloisons (enclosing metal strips). During this period, enamels with a design unique to Japan, in which flowers, birds and insects were used as themes, became popular. Designs also increasingly used areas of blank space. The two most famous enamelers of this era were Namikawa Yasuyuki and Namikawa Sōsuke, whose family names sound the same but who were not related. Namikawa Sōsuke promoted his work as technically innovative and adopted a style resembling fine paintings. Namikawa Yasuyuki was more conservative, opting for geometrical patterns but gradually becoming more pictorial during his career. Along with the two Namikawa, the Ando Cloisonné Company has produced many high-quality cloisonné works. Namikawa Yasuyuki's Vase with Birds and Flowers of the Four Seasons is one of the finest examples of cloisonné from this era. It won a gold medal at the 1900 Paris Exposition and was designated as an Important Cultural Property in 2025.
=== Courtship === Following the pioneering work of Alfred Henry Sturtevant and others, Benzer and colleagues used sexual mosaics to develop a novel fate mapping technique. This technique made it possible to assign a particular characteristic to a specific anatomical location. For example, this technique showed that male courtship behavior is controlled by the brain. Mosaic fate mapping also provided the first indication of the existence of pheromones in this species. Males distinguish between conspecific males and females and direct persistent courtship preferentially toward females thanks to a female-specific sex pheromone which is mostly produced by the female's tergites. Male flies sing to the females during courtship using their wings to generate sound, and some of the genetics of sexual behavior have been characterized. In particular, the fruitless gene has several different splice forms, and male flies expressing female splice forms have female-like behavior and vice versa. The TRP channels nompC, nanchung, and inactive are expressed in sound-sensitive Johnston's organ neurons and participate in the transduction of sound. Mutating the Genderblind gene, also known as CG6070, alters the sexual behavior of Drosophila, turning the flies bisexual.
Sources: en.wikipedia.org
clinafloxacin gatifloxacin moxifloxacin sitafloxacin prulifloxacin besifloxacin delafloxacin Two structurally related fourth-generation drugs, but formally not 4-quinolones, are gemifloxacin and trovafloxacin (removed from clinical use). In development:
As well as alpha and beta chains present in hemoglobin, about 3% of adult hemoglobin is made of alpha and delta globin chains. Just as with beta thalassemia, mutations that affect the ability of this gene to produce delta chains can occur.
A Scatchard plot (Rosenthal plot) can be used to show radioligand affinity. In this type of plot, the ratio of Bound/Free radioligand is plotted against the Bound radioligand. The slope of the line is equal to the negative reciprocal of the affinity constant (K). The intercept of the line with the X axis is an estimate of Bmax. The Scatchard plot can be standardized against an appropriate reference so that there can be a direct comparison of receptor density in different studies and tissues. This sample plot indicates that the radioligand binds with a single affinity. If the ligand were to have bound to multiple sites that have differing radioligand affinities, then the Scatchard plot would have shown a concave line instead.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.